ArticleActa oncologica (Stockholm, Sweden)2025
Adaptation of dose-prescription for vestibular schwannoma radiosurgery taking body contouring method and heterogeneous material into account.
Article in Acta oncologica (Stockholm, Sweden), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundMajority of vestibular schwannoma (VS) patients have undergone gamma-knife radiosurgery (GKRS) with favorable results. Clinical evidence is derived from doses calculated with a type-a algorithm, which in this case assumes all material to be water. A type-b algorithm (Convolution algorithm [CA]) taking tissue heterogeneity into account is available. Historically, body contour is defined using a 16-point approximation, whereas modern softwares generate the body from Magnetic Resonance Imaging (MRI). The accuracy in dose-calculation algorithms (DCA) and contouring method (CM) will have a significant influence in the relation between clinical outcome and dosimetric data. The objective was to investigate the impact of DCA and CMs on dose distribution while preserving treatment conditions.
methodsTreatment plans for 16 VS patients were recalculated in terms of DCA and CM. The difference in the dose covering 99% of the VS (DVS99%) depending on CM and DCA was estimated. The difference in DVS99% was used to adopt the prescription of new CA-based plans. CA-plans were recalculated to TMR10 to evaluate clinical treatability, as clinical evidence is derived from TMR10-doses.
resultsBoth CM and DCA had a significant impact on the dose to VS and surrounding structures. CM altered the doses homogenously by 2.1-3.3%, whereas DCA heterogeneously by 5.0-10.7%. An increase of 9.1[8.1, 10.0]% was found for DVS99% and the CA-plans recalculated into TMR10 resulted in clinically treatable plans.
interpretationWe conclude that transferring to more modern algorithms that take tissue heterogeneity into account heterogeneously alter dose distributions. This work establishes a safe pathway to adopt prescription dose for VS while preserving clinical treatability.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.